Company intelligence / Profile preview

Enrich Network

Branford, Connecticut, United Statesenrich.nihr.ac.uk ↗

Ownership: Private
Development stage: Other

Overview

Enrich Biosystems develops TROVO, a microfluidics-free high-throughput cell analysis and isolation platform. It enables rapid coculture screening of T-cell clones and other immune cells to accelerate discovery in cancer immunotherapy and regenerative medicine. The system preserves natural cell activity during selection, uses AI-driven grouping to identify promising clones efficiently, reduces process time/costs for labs working on T-cell/NK/stem/stem-like cells. The technology has been adopted by US/EU customers in academic/industry settings but does not itself have clinical trial results as it is a tool provider.

Modalities: Cell therapy discovery platformNot directly therapeutic, but enables T-cell, NK cell, and stem cell therapy development
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Enrich Network.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enrich Network.

Explore the full profile